Healthcare

AI during COVID-19; AR and VR in healthcare; FDNA's Face2Gene aids rare disease diagnosis; 5G healthcare applications.

AI speeds MND drug discovery with algorithm-led analysis

by Kenneth Ma | 31 August 2026

In 2021, Verge Genomics, a US-based AI drug discovery company, advanced an ALS candidate into Phase 1 trials. The compound, VRG50635, was not found through conventional screening. It surfaced via...

Technology

FDNA’s Face2Gene AI aids rare disease diagnosis from photos

by Kenneth Ma | 31 August 2026

Face2Gene, a platform developed by FDNA, applies deep learning to facial photographs to help clinicians identify rare genetic disorders. The tool does not make a final diagnosis. It ranks possible...

Science & Energy

5G Healthcare: Low Latency, New Applications

by Kenneth Ma | 31 August 2026

Fifth-generation cellular technology changes healthcare only where 4G LTE physically could not deliver. That is a narrower set of applications than the marketing suggests, but the ones that work are...

Technology

AR and VR in Healthcare: Clinical Reality After the Hype

by Kenneth Ma | 31 August 2026

Augmented reality and virtual reality have moved past the pilot phase in a handful of clinical settings, but the gap between what the technology promises and what the evidence supports...

Technology

What AI Actually Did During the COVID-19 Pandemic

by Kenneth Ma | 31 August 2026

The COVID-19 pandemic became the highest-stakes test ever for artificial intelligence in medicine. The WHO declared a Public Health Emergency of International Concern on 30 January 2020 and a pandemic...

Healthcare

MilliporeSigma, Lonza partner on cell therapy platform

by Kenneth Ma | 31 August 2026

MilliporeSigma, the U.S. and Canada life science business of Merck KGaA, introduced the MAST platform, a proprietary automated cell culture system, and simultaneously announced a strategic partnership with Lonza to...

Navigation